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Foreword 
The present report aims to provide a comprehensive picture of the pandemic situation of COVID-19 in the 
EU countries, and to be able to foresee the situation in the next coming days. 
We employ an empirical model, verified with the evolution of the number of confirmed cases in previous 
countries where the epidemic is close to conclude, including all provinces of China. The model does not 
pretend to interpret the causes of the evolution of the cases but to permit the evaluation of the quality of 
control measures made in each state and a short-term prediction of trends. Note, however, that the effects 
of the measures’ control that start on a given day are not observed until approximately 7-10 days later. 
 The model and predictions are based on two parameters that are daily fitted to available data: 
 a: the velocity at which spreading specific rate slows down; the higher the value, the better the 
control.  
 K: the final number of expected cumulated cases, which cannot be evaluated at the initial stages 
because growth is still exponential. 
We show an individual report with 8 graphs and a table with the short-term predictions for different 
countries and regions. We are adjusting the model to countries and regions with at least 4 days with more 
than 100 confirmed cases and a current load over 200 cases. The predicted period of a country depends on 
the number of datapoints over this 100 cases threshold, and is of 5 days for those that have reported more 
than 100 cumulated cases for 10 consecutive days or more. For short-term predictions, we assign higher 
weight to last 3 points in the fittings, so that changes are rapidly captured by the model. The whole 
methodology employed in the inform is explained in the last pages of this document. 
In addition to the individual reports, the reader will find an initial dashboard with a brief analysis of the 
situation in EU-EFTA-UK countries, some summary figures and tables as well as long-term predictions for 
some of them, when possible. These long-term predictions are evaluated without different weights to data-
points. We also discuss a specific issue every day.  
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(0) Executive summary – Dashboard  
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Global EU+EFTA+UK trends and needs 
Looking at the estimated EPG in the 
different countries that we include in 
the reports (both EU and non-EU), 
there are three countries that stand 
out. They are Brazil (EPGEST=1173), 
Sweden (EPGEST=1157) and Peru 
(EPGEST=938). As explained in our 
reports, EPGEST is calculated using the 
estimated 14-day attack rate rather 
than the reported one. This 
estimation of the real incidence is 
based on case fatality rate and the 
assumption of a 1 % lethality. 
According to this index, Sweden's 
situation is really worrying. In fact, 
this country has reported 4,468 
deaths, which corresponds to 44 
deaths per 100,000 inhabitants. Although the number of daily deaths is beginning to decline in recent days, 
its value remains quite high.  
Beyond Sweden, at EU+EFTA+UK level the other country that deserves attention is Portugal. It is a country 
that had a pretty good epidemiological behavior in the past month but, at the moment, it is the one that 
presents the highest reported EPG (EPGREP, based on reported data) after Sweden. The situation in Portugal 
must serve as a warning to other countries: surveillance and control must be maintained despite a good 
epidemiological situation. 
The analysis is focused on discussing the validity of 1% lethality assumption in Spain, given the results from 
the seroprevalence study. 
Highlights for specific countries  
France and Spain’s empiric reproduction number (ρ7) is not reliable yet, since it is still affected by 
inconsistencies and spikes in data. The one from Switzerland is also not reliable but, in this case, it is caused 
by the extremely low number of new cases (i.e., an increase in 1 or 2 cases may produce a significant increase 
in ρ7). Sweden shows a new increase in daily new cases, that had significantly decreased for a couple of days, 
and situate again at the level of 600-800. We have added a new column to the table in the next page, with 
the epidemiological situation given by the Biocom-Cov degree (see reports #79 and #80 from 1st and 2nd June). 
The map in the left shows current A14. The map in the right shows current EPG.                  




(1) ρ7 is the average of 7 consecutive ρ, but can still fluctuate. (2,3) EPG stands for Effective Growth Potential. EPGREP is the product of attack-rate of last 14 days per 105 inhabitants by 
ρ7 (empiric reproduction number). EPGEST is the product of estimated real attack-rate of last 14 days per 105 inhabitants and ρ7. Biocom-Cov degree is an epidemiological situation 
scale based on the level of last week’s mean daily new cases (https://upcommons.upc.edu/handle/2117/189661, https://upcommons.upc.edu/handle/2117/189808). 
 
Situation and trends per country 
Table of current situation in EU countries. Colour scale is relative except when indicated, this means that it is applied independently to each column, and distinguishes 
best (green) form worst (red) situations according to each of the variables. Last column (EPGEST) is assessed with estimated real 14-day attack rate (see report from 
22/04 for details). EPGREP is calculated with data reported by countries. EPGREP and EPGEST cannot be compared between them because scales are different, but can 
be independently used for estimating risk of countries according to reported or estimated real situation, respectively.    
 
Disclaimer: estimated active cases and estimated 14-day attack rate are assessed by assuming a lethality of 1 % (see report from 20 to 24 April, #37-41). This value can change in 




Analysis: Mortality in Spain. Supporting the assumption of 1% lethality. 
In Report #37(1) we discussed the 1% lethality as a reasonable scenario in Europe. From 27 April to 10 May, a 
seroprevalence study was carried out in Spain. The results of that study, which provided the relative presence 
of IgG anti SARS-Cov2 among population in different Spanish provinces, were used in our Report #65(2) to 
validate our estimates of the real number of cases in this country. In this analysis, we are recalling the results 
of the seroprevalence study in order to discuss the lethality of Covid-19.  
Next table shows the results of the seroprevalence in each of the Spanish regions and in the country as a 
whole. We show the total population of each Autonomous Community, the percentage of this population 
that would have overcome the disease according to the results of the above-mentioned study, and the 
absolute number of people corresponding to this percentage. 
Region Population 
Presence of  
IgG anti SARS-Cov2 







Andalucia 8414000 2,7% [2,2%-3,2%] 230000 [180000-270000] 
Aragon 1319000 4,9% [3,8%-6,3%] 65000 [50000-83000] 
Asturias 1023000 1,8% [1,3%-2,5%] 18000 [13000-26000] 
Baleares 1149000 2,4% [1,6%-3,5%] 26000 [18000-40000] 
Canarias 2153000 1,8%  [1,1%-2,8%] 39000 [24000-60000] 
Cantabria 581000 3,2% [2,1%-5,0%] 19000 [12000-29000] 
Castilla-La Mancha 2033000 10,8% [9,3%-12,4%] 220000 [190000-250000] 
Castilla y Leon 2400000 7,2% [6,3%-8,1%] 170000 [150000-190000] 
Catalunya 7675000 5,9%  [4,9%-6,9%] 450000 [380000-500000] 
Com. Valenciana 5004000 2,5% [1,9%-3,2%] 130000 [95000-160000] 
Extremadura 1068000 3,0% [2,2%-4,1%] 32000 [23000-44000] 
Galicia 2699000 2,1% [1,7%-2,6%] 57000 [46000-70000] 
Madrid 6663000 11,3% [9,8%-13,0%] 750000 [650000-870000] 
Murcia 1494000 1,4% [0,8%-2,4%] 21000 [12000-36000] 
Navarra 654000 5,8% [4,3%-7,6%] 38000 [28000-50000] 
Euskadi 2208000 4,0% [3,1%-5,2%] 88000 [68000-115000 ] 
La Rioja 317000 3,3% [2,4%-4,4%] 10000 [7600-14000] 
Spain 47025000 5,0% [4,7%-5,4%] 2350000 [2200000-2500000] 
These values are assumed to correspond to the cases at around 13 April, considering an average delay 
between infection and a significant probability of positivize a serological test of 21 days. Given that the mean 
delay between infection and death, for the people that cause exitus, is about 18 days, we can estimate the 
lethality in each Spanish region by comparing the serological study results with the deaths reported by 1 May. 
This evaluation situates lethality in Spain around 1%, which is the value that was adopted in our previous 
analyses.  
This 1% would correspond mainly to deaths in hospitals, which would be deaths directly caused by Covid-19. 
Future studies about the excess in mortality based on MoMo data should estimate the real percentage of 
deaths directly caused by Covid-19, those that dye because of another pathology that may (or may not) be 




worsened by Covid-19, and those deaths related with collateral effects of the pandemic (e.g., hospitals 
saturation and sedentarism, among others).  
Next table shows the lethality in each Spanish region and in the country as a whole, using the seroprevalence 
results as explained above. Note that lethality in La Rioja is extremely high. In fact, this 3.2% suggest that the 
samples for the seroprevalence study were not appropriately chosen. We also indicate in the table the mean 














Andalucia 1253 0,6% [0,5%-0,7%] 41,84 38% 
Aragon 761 1,2% [0,9%-1,5%] 44,81 74% 
Asturias 270 1,5% [1,1%-2,0%] 48,28 61% 
Baleares 197 0,7% [0,5%-1,1%] 41,48 42% 
Canarias 140 0,4% [0,2%-0,6%] 42,49 7% 
Cantabria 193 1,0% [0,7%-1,6%] 45,57 62% 
Castilla-La Mancha 2534 1,2% [1,0%-1,3%] 43,08 40% 
Castilla y Leon 1788 1,0% [0,9%-1,2%] 47,7 72% 
Catalunya 5137 1,1% [1,0%-1,4%] 42,83 20% 
Com. Valenciana 1258 1,0% [0,8%-1,3%] 43,37 37% 
Extremadura 458 1,4% [1,0%-1,9%] 44,34 67% 
Galicia 563 1,0% [0,8%-1,2%] 47,24 45% 
Madrid 8292 1,1% [1,0%-1,3%] 42,35 72% 
Murcia 132 0,6% [0,4%-1,1%] 40,55 46% 
Navarra 460 1,2% [0,9%-1,6%] 43,27 48% 
Euskadi 1321 1,5% [1,2%-1,9%] 45,45 37% 
La Rioja 334 3,2% [2,4%-4,4%] 44,49 57% 
Spain 25097 1,1% [1,0%-1,1%] 43,27 51% 
The numbers in this table reinforce the importance of two factors: (1) age is an important risk factor on the 
prognosis of the disease, and (2) protection of residences is essential to prevent mortality to grow. The 
following figures illustrate these issues. We have plotted the lethality of each region versus the mean age of 
population (left) and versus the number of reported deaths in residences.   
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These figures suggest that those regions with a lower mean age of population would have had less Covid-
19 lethality than those with a higher mean age. Moreover, it is clear from the figure in the right that the 
region with significantly lower percentage of deaths in nursing homes also show a significantly lower 
lethality. Updated results of the second round of the seroprevalence study (to be published tomorrow by 
Spanish government) should permit a more detailed analysis to estimate the lethality with higher accuracy, 




Situation and trends in other countries 
Table of current situation in a sample of non-EU countries. Colour scale is relative except when indicated, this means that it is applied independently to each column, 
and distinguishes best (green) form worst (red) situations according to each of the variables. EPGREP and EPGEST cannot be compared between them because scales 
are different, but can be independently used for estimating risk of countries according to reported or estimated real situation, respectively.    
 
Disclaimer: estimated active cases and estimated 14-day attack rate are assessed by assuming a lethality of 1 % (see report from 20 to 24 April, #37-41). This value can change in 
countries where suspicious deaths are reported as well (real values would be lower) and in countries where incidence among elderly people was minor (real values would be higher).  
 
 (1) ρ7 is the average of 7 consecutive ρ, but can still fluctuate. (2,3) EPG stands for Effective Growth Potential. EPGREP is the product of attack-rate of last 14 days per 105 inhabitants by 
ρ7 (empiric reproduction number). EPGEST is the product of estimated real attack-rate of last 14 days per 105 inhabitants and ρ7. Biocom-Cov degree is an epidemiological situation 






Time indicators by country 
These tables summarize a few time indicators for each country: time since 50 cases were reported, time 
interval between an attack rate of 1/105 inhabitants and an attack rate of 10/105 inhabitants, and time 





































Evaluated with the whole historical series. See figure in the next page. Up-left: Predictions of maximum 
incidences per country (total final expected attack rate per 105 inh.). Up-right: Predictions of maximum 
absolute number of cases per country (K, in log scale). Blue lines indicate current situation. Bottom-left: Time 
in which peak in new cases was achieved / will be achieved. Bottom-right: Time at which 90 % of K was 








Situation and trends in Italian regions3 
Situation and trends 
 
Disclaimer: estimated active cases and estimated 14-day attack rate are assessed by assuming a lethality of 1 % (see 
report from 20 to 24 April, #37-41). This value can change in countries where suspicious deaths are reported as well 
(real values would be lower) and in countries where incidence among elderly people was minor (real values would be 
higher).  
 (1) ρ7 is the average of 7 consecutive ρ, but can still fluctuate. (2,3) EPG stands for Effective Growth Potential. EPGREP is the 
product of attack-rate of last 14 days per 105 inhabitants by ρ7 (empiric reproduction number). EPGEST is the product of 
estimated real attack-rate of last 14 days per 105 inhabitants and ρ7. Biocom-Cov degree is an epidemiological situation 





                                                            







Legend: Countries’ reports details 
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Data obtained from  https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases  
 

































































Data obtained from https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases  
 
(2) Analysis and prediction of COVID-19 


























 Data obtained from: https://github.com/pcm-dpc/COVID-19/tree/master/dati-andamento-nazionale 
(3) Analysis and prediction of COVID-19























































(1) Data source 
Data are daily obtained from World Health Organization (WHO) surveillance reports4, from European Centre 
for Disease Prevention and Control (ECDC)5 and from Ministerio de Sanidad6. These reports are converted 
into text files that can be processed for subsequent analysis. Daily data comprise, among others: total 
confirmed cases, total confirmed new cases, total deaths, total new deaths. It must be considered that the 
report is always providing data from previous day. In the document we use the date at which the datapoint 
is assumed to belong, i.e., report from 15/03/2020 is giving data from 14/03/2020, the latter being used in 
the subsequent analysis.  
(2) Data processing and plotting 
Data are initially processed with Matlab in order to update timeseries, i.e., last datapoints are added to 
historical sequences. These timeseries are plotted for EU individual countries and for the UE as a whole: 
 Number of cumulated confirmed cases, in blue dots 
 Number of reported new cases 
 Number of cumulated deaths  
Then, two indicators are calculated and plotted, too: 
 Number of cumulated deaths divided by the number of cumulated confirmed cases, and reported as 
a percentage; it is an indirect indicator of the diagnostic level. 
 ρ: this variable is related with the reproduction number, i.e., with the number of new infections 
caused by a single case. It is evaluated as follows for the day before last report (t-1): 
𝜌𝜌(𝑡𝑡 − 1) =
𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡) + 𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡 − 1) + 𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡 − 2)
𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡 − 5) + 𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡 − 6) + 𝑁𝑁𝑛𝑛𝑛𝑛𝑛𝑛(𝑡𝑡 − 7)
 
where Nnew(t) is the number of new confirmed cases at day t.  
(3) Classification of countries according to their status in the epidemic cycle 
The evolution of confirmed cases shows a biphasic behaviour:  
(I) an initial period where most of the cases are imported; 
(II) a subsequent period where most of new cases occur because of local transmission.  
Once in the stage II, mathematical models can be used to track evolutions and predict tendencies. Focusing 
on countries that are on stage II, we classify them in three groups: 
• Group A: countries that have reported more than 100 cumulated cases for 10 consecutive days or 
more; 
• Group B: countries that have reported more than 100 cumulated cases for 7 to 9 consecutive days; 
• Group C: countries that have reported more than 100 cumulated cases for 4 to 6 days. 
 




https://github.com/datadista/datasets/tree/master/COVID%2019 , https://covid19.isciii.es/ 
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(4) Fitting a mathematical model to data 
Previous studies have shown that Gompertz model7 correctly describes the Covid-19 epidemic in all analysed 
countries. It is an empirical model that starts with an exponential growth but that gradually decreases its 
specific growth rate. Therefore, it is adequate for describing an epidemic that is characterized by an initial 
exponential growth but a progressive decrease in spreading velocity provided that appropriate control 
measures are applied.   
Gompertz model is described by the equation:  





where N(t) is the cumulated number of confirmed cases at t (in days), and N0 is the number of cumulated 
cases the day at day t0. The model has two parameters: 
 a is the velocity at which specific spreading rate is slowing down; 
 K is the expected final number of cumulated cases at the end of the epidemic. 
This model is fitted to reported cumulated cases of the UE and of countries in stage II that accomplish two 
criteria: 4 or more consecutive days with more than 100 cumulated cases, and at least one datapoint over 
200 cases. Day t0 is chosen as that one at which N(t) overpasses 100 cases. If more than 15 datapoints that 
accomplish the stated criteria are available, only the last 15 points are used. The fitting is done using Matlab’s 
Curve Fitting package with Nonlinear Least Squares method, which also provides confidence intervals of 
fitted parameters (a and K) and the R2 of the fitting. At the initial stages the dynamics is exponential and K 
cannot be correctly evaluated. In fact, at this stage the most relevant parameter is a. Fitted curves are 
incorporated to plots of cumulative reported cases with a dashed line. Once a new fitting is done, two plots 
are added to the country report: 
 Evolution of fitted a with its error bars, i.e., values obtained on the fitting each day that the analysis 
has been carried out;  
 Evolution of fitted K with its error bars, i.e., values obtained on the fitting each day that the analysis 
has been carried out; if lower error bar indicates a value that is lower than current number of cases, 
the error bar is truncated. 
These plots illustrate the increase in fittings’ confidence, as fitted values progressively stabilize around a 
certain value and error bars get smaller when the number of datapoints increases. In fact, in the case of 
countries, they are discarded and set as “Not enough data” if a>0.2 day-1, if K>106 or if the error in K 
overpasses 106. 
It is worth to mention that the simplicity of this model and the lack of previous assumptions about the Covid-
19 behaviour make it appropriate for universal use, i.e., it can be fitted to any country independently of its 
socioeconomic context and control strategy. Then, the model is capable of quantifying the observed 
dynamics in an objective and standard manner and predicting short-term tendencies.  
(5) Using the model for predicting short-term tendencies 
The model is finally used for a short-term prediction of the evolution of the cumulated number of cases. The 
predictions increase their reliability with the number of datapoints used in the fitting. Therefore, we consider 
three levels of prediction, depending on the country: 
                                                            
7 Madden LV. Quantification of disease progression. Protection Ecology 1980; 2: 159-176. 
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• Group A: prediction of expected cumulated cases for the following 3-5 days8; 
• Group B: prediction of expected cumulated cases for the following 2 days; 
• Group C: prediction of expected cumulated cases for the following day. 
The confidence interval of predictions is assessed with the Matlab function predint, with a 99% confidence 
level. These predictions are shown in the plots as red dots with corresponding error bars, and also gathered 
in the attached table. For series longer than 9 timepoints, last 3 points are weighted in the fitting so that 
changes in tendencies are well captured by the model. 
(6) Estimating non-diagnosed cases 
Lethality of Covid-19 has been estimated at around 1 % for Republic of Korea and the Diamond Princess 
cruise. Besides, median duration of viral shedding after Covid-19 onset has been estimated at 18.5 days for 
non-survivors9 in a retrospective study in Wuhan. These data allow for an estimation of total number of 
cases, considering that the number of deaths at certain moment should be about 1 % of total cases 18.5 days 
before. This is valid for estimating cases of countries at stage II, since in stage I the deaths would be mostly 
due to the incidence at the country from which they were imported. We establish a threshold of 50 reported 
cases before starting this estimation.  
Reported deaths are passed through a moving average filter of 5 points in order to smooth tendencies. Then, 
the corresponding number of cases is found assuming the 1 % lethality. Finally, these cases are distributed 
between 18 and 19 days before each one.  
 
                                                            
8 At this moment we are testing predictions at 4 days for countries with more than 100 cumulated cases for 13-15 
consecutive days, and 5 days for 16 or more days.  
9 Zhou et al., 2020. Clinical course and risk factors for mortality of adult 
inpatients with COVID-19 in Wuhan, China: a retrospective 
cohort study. The Lancet; March 9, doi: 10.1016/S0140-6736(20)30566-3 
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